S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Nano-X Imaging Facing Class Action Lawsuit Over Alleged Deception

Investors who purchased Nano-X Imaging Ltd. securities between March 31, 2025, and April 17, 2026, face a critical deadline to join a class action lawsuit. The Schall Law Firm is spearheading the litigation, alleging that the company misled the market regarding product demand and operational efficiency during the specified period.

Nano-X Imaging Facing Class Action Lawsuit Over Alleged Deception
Photo: Bio & News

The complaint filed against Nano-X (NASDAQ: NNOX) centers on violations of the Securities Exchange Act of 1934. According to the litigation, the company issued false and misleading statements that artificially inflated investor expectations. While Nano-X claimed significant growth in product demand and internal efficiency, the lawsuit asserts that these figures were disconnected from reality. The firm argues that the company’s misalignment with customer needs led to an unsustainable increase in cash burn, ultimately damaging shareholders when the true financial state of the business came to light.

Shareholders who incurred losses during the class period have until August 11, 2026, to contact the Schall Law Firm. Brian Schall, based in Los Angeles, is managing inquiries from investors seeking to discuss their rights. As the class remains uncertified, shareholders currently act as absent members, meaning no formal legal representation is established unless they actively join the proceedings.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!